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This concise total synthesis of the Thomsen-Nouveau (Tn)
glycoconjugate was accomplished using a palladium-catalyzed
coupling between the glycosyl donor and Fmoc-protected
serine acceptor. This is, to the best of our knowledge, the
shortest synthesis reported from galactose for preparing this
essential building block for large-scale solid phase peptide
synthesis.
Cancer is a leading cause of death globally. Despite constant
advances in treatment, the percentage of cancer-related deaths
is expected to increase in the developed world as other fatal
conditions are continuously becoming better controlled.1
Although there is ever accelerating innovation in the treatment
of cancer, progress remains agonizingly slow due to the
enormous diversity of mutations responsible for causing
cancer.2 The current primary triad of surgery and/or
radiation/chemotherapy both in tandem or individually can be
highly effective;3 but success is greatly dependent on a series of
variables including (but not limited to): the location of the
disease, metastasis status, types of mutations present, and
stage at detection. Therapeutic options are particularly lacking
for late-stage cancers. Despite a few targeted therapies recently
becoming available,4 especially for certain subtypes of breast5
and prostate6 cancer, in many cases these pharmaceutical
interventions still often result in short term improvement, with
disease recurrence emerging as the cancer mutates to resist the
treatment. We consequently need completely orthogonal
therapeutic modalities to complement this therapeutic triad.
Cancer vaccines are a promising avenue as they could re-engage
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the body’s immune system to the battle. For many purposes,
cancer can be defined as uncontrolled cell growth that has
evaded the immune system, and will eventually progress to the
death of the host1: the vast majority of precancerous clusters
are hypothesized to be cleared by the immune system long
before they can develop into a tumor.7, 8 When looking to
activate the immune systems, vaccines are particularly
attractive;9, 10 however, they require the identification of
biomarkers correlated with cancer. Unfortunately, many
oncotargets are simply upregulated in cancer. As they are also
present on healthy cells, they are inappropriate vaccine targets
as stimulation would initiate a systemic and very dangerous
immune response. Tumor-Associated Carbohydrate Antigens
(TACAs) are different as they are not found on healthy adult
tissue, yet are found on over 90% of biopsied carcinomas (ie.
breast, ovarian, colon, lung, and prostate cancers). 11 This
discrepancy likely arises because these TACAs are found at the
reducing-end of surface glycans, and are anchored to the amino
acids or lipids of the membranes. In healthy tissue they are
always further elaborated into larger glycostructures. However
in cancer, the misregulation of glycosyl transferases responsible
for this elaboration ensures that these TACA scaffolds remain
naked, missing the additional residues. Their precise role in
oncogenesis is unclear, but overexpression is generally
correlated with a poor prognosis.1, 12 These carbohydrate
antigens have, when incorporated into glycopeptides or other
immunogenic scaffolds, formed the basis of the development of
anti-tumor immunotherapies through the induction of a specific
immune response against cancer cells. 13-16 However, ready
access to these materials remains a significant challenge, and a
simple scalable synthesis is required. As part of an extensive
carbohydrate vaccine effort, we needed a route to produce the
simplest TACA building block appropriate for solid phase
peptide synthesis on multigram, and up to 100g scale: the
Fmoc-protected peracetylated Tn antigen (1), α-2-deoxy-2-Nacetylamino-d-galactose (GalNAc) O-linked to a serine residue.
Although this molecule has been prepared repeatedly in the
past,17 we found many of the simple published routes were 1: A)
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performed. This hemiacetal was converted to a large number of
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different activating groups (see references above), but yields for
introducing the activating group were highly variable and the
Figure 1. Danishefsky’s first generation synthesis of the Fmoc-protected
peracetylated Tn antigen (1);18 B) Danishefsky’s second generation synthesis of
the Fmoc-protected Tn antigen.18

inconsistent batch-to-batch and couldn’t always be reproduced

Scheme 1: Synthesis of the Tn Antigen, protected for solid-phase peptide
synthesis. Yields are reported as ranges of yields from multiple trials and multiple
operators. BRSM indicates yield based on recovered starting material, with the
assumption that the recovered starting material can be resubjected to reaction
conditions.

if the chemist doing the reactions changed. 18-22 Furthermore,
published routes often required complex protecting group
strategies that increased the step and purification count,
decreasing yield (Figure 1). We wish to report the route we are
using for this scale-up and that can be readily executed by a
junior undergraduate student.
Our synthetic approach begins with a series of wellprecedented steps as outlined in Scheme 1. A medium scale
peracetylation of d-Galactose (100g scale) providing a 78% yield
of the β anomer after recrystallization from methanol.
Subsequent bromination in strong acid yielded the galactosyl
bromide 3 in good yield after precipitation. Treatment of the
unstable bromosugar23 with zinc metal in acetonitrile at reflux,
provides bench stable galactal 4 in high yield. Although other
approaches were explored,18 this route proved to be the most
reliable access to this material, with no chromatography
needed.
To introduce the C2-amine, we found that Lemieux’s ceric
ammonium nitrate (CAN)-mediated azidonitration was highly
effective and robust providing crude 5,24 that readily hydrolyses
the anomeric nitrate to provide reducing sugar 6. This
transformation, although effective, does result in the formation
of inseparable byproducts and although 6 is crystallizable, this
is very slow and inefficient, and so chromatography must be

Table 1. Attempted Conditions for the conversion of TCA 7 to glycoconjugate 8.

subsequent glycosylations inevitably inconsistent. Schmidt’s
trichloroacetamidates (TCA) were the most promising.25, 26
General protocols call for the use of potassium carbonate

however, we found that the more soluble cesium carbonate
reduced reaction times from several hours to mere minutes
with a concomitant reduction in product decomposition,
leading to higher yields. This intermediate should be used
immediately upon isolation to minimize background hydrolysis.
TACAs are generally made to be incorporated into peptides.
This means that the resulting product should have an Fmocprotected amino group and a free acid. Fmoc amino acids are
notoriously challenging to couple and manipulate compared to
Boc-protected analogues, and a common approach involves
making the glycoconjugate, deprotecting the Boc group, and
installing the Fmoc. This is inefficient especially as the price
difference between Boc and Fmoc amino acids continues to
close, and as Fmoc-installation is non-trivial. Similarly, we
wanted to avoid conditions that required the carboxylate group
on the amino acid to be protected; minimizing steps on the
more complex molecule was a central requirement of our
approach, both to minimize linear step count and to minimize
the risks inherent in any transformation on valuable material.
Consequently we only focused on published methods that used
Fmoc-Ser(OH)-OH as the partner. All these routes use one of
only a handful of Lewis acids as promoter. These proved
unsuccessful (Table 1). The best result, 17%, was obtained with
TMSOTf with a 24 hour reaction time with moderate
conversion. Leaving the reaction, sealed, for longer time we
started observing product decomposition which lowered the
isolated yield and also complicated isolation due to the higher
impurity profile. Generally, the reactions were sluggish with
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This result remains far from ideal, and reaction optimization and
the search for alternatives to Pd2+ salts is currently underway in
the group, but this was certainly the most robust of the dozens
of conditions we screened to access this material.
The final step before global deprotection is a one pot
reduction and acetylation to form the NHAc functionality at C2. Standard reducing conditions afforded 1 in high yield, and
ready for incorporation into glycopeptides. Our design-ofexperiment study on the Nguyen glycosylation and screening of
alternate metal catalysts will be reported on in due course;
samples of the Fmoc-protected Tn antigen are available for
collaboration or at cost.

Conclusions
Figure 2. Proposed mechanisms of the Nguyen glycosylation in the presence or
absence of a cis-C-2 ether. Proposed mechanism in the presence of a cis C-2 azide

slow consumption of starting material, and then product
decomposition under the reaction conditions. All Lewis acids
were freshly distilled under Schlenk technique, all solvents were
obtained using air-free techniques directly from ketal stills, or a
solvent purification system. All transfers were made using air
free techniques. Advantageous water was not a serious
challenge explaining the limited conversions.
Before abandoning TCAs as a viable system and returning to
glycosyl sulfoxides, we considered Nguyen’s unusual palladium
(II) catalyst, Pd(CH3CN)4(BF4)2, as a promoter.27-29 Nguyen used
it as a promoter for the formation of β-glycosides through a
proposed modified anchimeric effect where the Pd chelates to
a C2 ether as well as the nitrogen of the TCA, keeping the TCA
localized to the bottom face of the oxocarbenium, forcing βattack. In the case of mannose or rhamnose where the C-2 ether
is axial, this chelation is impossible, and an oxocarbenium
intermediate
followed
by
anomeric-effect-driven
αglycosylation was observed (Figure 2). This meant that this
chemistry was incapable of providing α-anomers in the
presence of an equatorial substituent at C2; however, we could
find no examples where galactose was evaluated, nor any
examples with a C-2 azide. As the azide should not complex to
the Pd in the same fashion as the etheric oxygen, we believed
that we would pass through an oxocarbenium instead, and the
anomeric effect would preferentially drive the formation of the
desired α-product. Some reaction screening provided a new set
of conditions that reliably formed 8 from 7 using the Nguyen
glycosylation in up to 38% yield of the desired α-product of the
with an initial α to β ratio of approximately 3:1 (total combined
isolated yields of both anomers up to 50%). Importantly, the
starting materials can be recovered from the reaction mixture
allowing for resubmission to conditions (longer reaction times
started leading to product decomposition; yield based on
recovered starting material is far higher, 68-91% combined
anomer yield, making this cost effective as the material
produced to that point need not be unnecessarily yeeted in this
penultimate step). The reaction was conducted by four different
chemists (undergraduate, graduate, and postdoctoral) with just
the written protocol, with the obtained yields being consistent.

This is the first readily scalable total synthesis of a suitably
protected Tn antigen for SPPS, with a lower step-count than any
other report in the literature and incorporating a robust and
reproducible Nguyen glycosylation as the key step. The overall
yield for the process is 7% from Galactose, with only two
chromatography steps, and the process can be conducted on
scale in under two weeks by a practitioner skilled in the art. Or
by a skilled undergraduate student while carrying out a full
course-load in about 6 weeks. The intermediates are, for the
most part, bench stable making this a very simple way to access
this extremely important building block for glycopeptide
chemistry.
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